Compass Therapeutics, Inc. (CMPX) Reports In-Line Q2 EPS
Tweet
Share
E-mailGet Alerts CMPX Hot Sheet
Join SI Premium – FREE
Compass Therapeutics, Inc. (NASDAQ: CMPX) reported Q2 EPS of ($0.10), in-line with the analyst estimate of ($0.10). Revenue for the quarter came in at $850 million.
For earnings history and earnings-related data on Compass Therapeutics, Inc. (CMPX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sanmina (SANM) Tops Q3 EPS by 54c, Updates Guidance
- First Guaranty Bancshares, Inc. (FGBI) Tops Q2 EPS by 8c
- Peapack-Gladstone Financial (PGC) Misses Q2 EPS by 2c, Beats on Revenue
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
